α-galactosylceramide 付加細胞投与によるNKT 細胞活性化を介した抗腫瘍免疫療法
書誌事項
- タイトル別名
-
- Cancer Immunotherapy via Activation of NKT Cells by Administration of α-galactosylceramide Lorded Cells
この論文をさがす
抄録
<p>Recently, cancer immunotherapy is noticed as a new therapy of cancer, in addition to surgery, chemotherapy, and radiotherapy. We have been focused on alpha-galactosylceramide (αGalCer) loaded cell treatment, that can activate invariant NKT cell, and consequently activate both innate and acquired immunity by intravenous injection. Especially, we focus on allogeneic dendritic cells pulsed with αGalCer (DCG ) treatment because of its therapeutic efficacy. Our research clarified allogeneic DCG treatment prolonged survival similar to syngeneic DCG treatment. And also we revealed allogeneic DCG treatment induced similar antitumor effect regarding NK and NKT cell activity compared to syngeneic DCG treatment. As a result, our data shows allogeneic DCG treatment could be substituted for syngeneic DCG treatment. Furthermore, our results also show that the therapeutic value of allogeneic DCG is significantly better than syngeneic DCG in a kind of tumor cell lines. According to an examination of cytotoxic activity after treatment, this superiority would be caused by enhancement of antitumor effect with acquired immunity. We are currently working on creating therapeutic models by adopting antigen-specific T cells, and examine this enhancement.</p>
収録刊行物
-
- サイトメトリーリサーチ
-
サイトメトリーリサーチ 27 (1), 7-12, 2017
日本サイトメトリー学会
- Tweet
詳細情報
-
- CRID
- 1390001204472875008
-
- NII論文ID
- 130006832458
-
- ISSN
- 24240664
- 09166920
-
- 本文言語コード
- ja
-
- データソース種別
-
- JaLC
- CiNii Articles
- KAKEN
-
- 抄録ライセンスフラグ
- 使用不可